- Home
- ATOS vs GROW Comparison
ATOS vs GROW Comparison
Compare ATOS & GROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATOS | GROW |
|---|---|---|
| Founded | 2009 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.2M | 32.7M |
| IPO Year | 2010 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ATOS | GROW |
|---|---|---|
| Price | $2.12 | $3.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 300.7K | 31.8K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 3.53% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | $1,758.00 | ★ $23,850,609.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $11.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $2.23 |
| 52 Week High | $7.56 | $3.65 |
Technical Indicators
Market Signals| Indicator | ATOS | GROW |
|---|---|---|
| Relative Strength Index (RSI) | 29.03 | 66.34 |
| Support Level | $0.58 | $3.10 |
| Resistance Level | $6.18 | $3.37 |
| Average True Range (ATR) | 0.17 | 0.13 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 42.00 | 60.98 |
Price Performance
Historical ComparisonAbout ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.